Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible
patients will receive open-label treatment with rivastigmine capsules plus memantine tablets
as add on therapy. This study is designed to evaluate the safety and tolerability of add on
therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)